Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
about
Polymorphisms in DNA repair genes in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Gastrointestinal stromal tumors (GIST): Facing cell death between autophagy and apoptosis.An exploratory association of polymorphisms in angiogenesis-related genes with susceptibility, clinical response and toxicity in gastrointestinal stromal tumors receiving sunitinib after imatinib failure.Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis.Integrating miRNA and gene expression profiling analysis revealed regulatory networks in gastrointestinal stromal tumors.
P2860
Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Pharmacogenetics of tyrosine k ...... and chronic myeloid leukemia.
@en
type
label
Pharmacogenetics of tyrosine k ...... and chronic myeloid leukemia.
@en
prefLabel
Pharmacogenetics of tyrosine k ...... and chronic myeloid leukemia.
@en
P2860
P50
P1476
Pharmacogenetics of tyrosine k ...... and chronic myeloid leukemia.
@en
P2093
Patrizia Hrelia
Sabrina Angelini
P2860
P304
P356
10.1080/17425255.2016.1184649
P407
P577
2016-05-05T00:00:00Z